TL;DR
- Company: Sato Pharmaceutical Co., Ltd., 1-5-27 Moto-Akasaka, Minato-ku, Tokyo, Japan (manufacturing facility: 1468 Hazama-Machi, Hachioji, Tokyo).
- Date: Warning Letter 320-26-75 issued May 18, 2026 (MARCS-CMS 723059).
- Classification: CGMP / Drugs / Adulterated (OTC drug products).
- Key citations: An ISO 5 aseptic filling line FDA called "fundamentally unsuitable," six media fill failures between November 2022 and February 2025 (211.113(b)); no stability-indicating methods and unmonitored impurity peaks (211.165(b) and 211.166(a)); OTC products released without required microbiological testing, including for Burkholderia cepacia complex (211.160(b)).
- Consequence: Sato voluntarily halted sterile-drug production for the U.S. market. FDA found the firm's response inadequate on all three citations and wants a comprehensive independent risk assessment before production resumes.
| Company | Location | Letter # | Issued | Issuing Office | Inspection Dates | Classification |
|---|---|---|---|---|---|---|
| Sato Pharmaceutical Co., Ltd. | 1468 Hazama-Machi, Hachioji, Tokyo, Japan (manufacturing facility) | 320-26-75 (MARCS-CMS 723059) | May 18, 2026 | CDER | November 13–21, 2025 | CGMP / Drugs / Adulterated |
Picture the moment right after an intervention on a filling line. An operator reaches in to clear a jam, pulls back, and the air over the open product is supposed to snap back into a clean, one-directional flow before anything can settle into it. That's the whole premise of an ISO 5 aseptic zone: air moves one way, down and away from the product, no exceptions. Now picture that same air being pulled the wrong direction, upward, off the line, every time someone reaches in. That's what FDA investigators say they found at Sato Pharmaceutical Co., Ltd.'s Hachioji, Tokyo manufacturing site, laid out in FDA Warning Letter 320-26-75, issued May 18, 2026 and addressed to President and CEO Seiichi Sato.
FDA inspected the Hachioji facility November 13–21, 2025. Three citations followed, covering the aseptic filling line, the stability program meant to catch problems after the fact, and the microbiological testing meant to catch problems before release. Read together, they describe a sterile operation where none of the usual safety nets were built the way they needed to be.
The three citations, in order
21 CFR 211.113(b) — the aseptic filling line could not maintain a state of control. FDA doesn't hedge on this one. The ISO 5 area used for aseptic filling of certain OTC drug products is "fundamentally unsuitable for its intended use," the letter states, and the design and capability of the line, which it calls the "(b)(4) Line," weren't sufficient to establish and maintain a state of control. Between November 2022 and February 2025, attempts to validate that line produced at least six media fill failures. Six. Investigators also documented significant microbiological and foreign particulate contamination on the line, which manufactures OTC products for the U.S. market.
The design problem sits in the airflow. Air intake vents for the Grade A laminar airflow system, a restricted access barrier system (RABS), were positioned so an intervention pulled air upward, away from the line, instead of protecting it. First-pass air never reached the filling zone; the critical ISO 5 area sat unprotected while sterile product was exposed. The smoke studies meant to verify airflow were themselves deficient: the smoke source moved too quickly to evaluate on video, and in some cases the technician's own body blocked the view. A study built to prove the air behaves correctly couldn't show whether it did.
21 CFR 211.165(b) and 211.166(a) — no adequate stability program, and impurity peaks nobody was watching. Sato had no stability-indicating methods for the OTC products it ships to the U.S., and no adequate program confirming those products would hold their chemical and microbiological properties through the labeled shelf life. Twelve-month and 24-month stability chromatograms for one product showed an early-eluting peak, appearing before the main peak, not present at release. The firm calls it a "degradation impurity" internally but doesn't monitor or report it during stability testing. A second product showed similar unidentified peaks at 12 months. The programs also skipped required attributes outright: one omitted viscosity, degradation products, an active-ingredient assay, and dose uniformity; another omitted content assay, degradation products, particulate matter, and weight loss.
21 CFR 211.160(b) — OTC products released without required microbiological testing. Sato manufactures OTC products containing a redacted inactive ingredient and released several to the U.S. market without required microbiological testing, including testing for Burkholderia cepacia complex. FDA is specific about why that organism matters: B. cepacia is an "opportunistic pathogen of particular concern for patients with compromised immune systems or chronic lung conditions." A product can look fine on paper and still carry an organism dangerous to the patients who can least afford it.
Why FDA found the response inadequate
Sato responded to its Form FDA 483 on December 12, 2025. On the aseptic line, the firm committed to replacing bottle holders and revising smoke study procedures, with plans to update the line before running new media fills in October 2026. FDA's read? That plan treats the symptoms and skips the diagnosis. The response failed to address the "broader systemic failures in aseptic process design, environmental control, and contamination prevention" behind six failed media fills, and these systemic issues, FDA states plainly, "pose an unacceptable risk to patients."
The pattern repeats across all three citations. On stability, Sato is running a retrospective chromatogram investigation and says it will start monitoring all peaks going forward. Fine, as far as it goes. But FDA notes the firm still hasn't supplied stability-indicating methods, degradation-product identification, or health hazard evaluations for products already on U.S. shelves. On microbiological testing, Sato committed to testing reference samples for B. cepacia going forward, but provided no reserve-sample results, no health hazard evaluation for released batches, and no patient risk assessment. Forward-looking fixes without a backward-looking accounting leave the same open question three times over: what happens to what's already out there?
FDA acknowledged the voluntary halt in sterile-drug production for the U.S. market. Given "the fundamental flaws documented in your sterile production line," it wants either a written commitment not to resume production until corrective actions are complete and a CAPA plan is discussed with the agency, or a written commitment to stop sterile manufacturing for the U.S. market permanently. FDA also recommended, under 21 CFR 211.34, a qualified CGMP consultant to run a six-system audit: quality, facilities and equipment, materials, production, packaging and labeling, and laboratory controls.
The letter does not mention a recall, an import alert, or prior warning letter history for this facility. It closes with the standard 15-working-day response window and the standard warning that unresolved violations may lead to refusal of admission under 21 U.S.C. 381(a)(3), plus possible withholding of approval for new applications listing this facility. Signed by Francis Godwin, Director, Office of Manufacturing Quality, Office of Compliance, CDER.
What this means for other sterile OTC manufacturers
Three patterns extend past one facility in Hachioji. First, a validated line isn't a suitable line. Six media fill failures over roughly two and a half years isn't normal validation friction; it's a design that fights the airflow protection it's supposed to provide. Replacing hardware after the fact doesn't answer the design question.
Second, a stability program has to look for what it doesn't expect, not just confirm what it does. An early-eluting peak that appears at 12 and 24 months but wasn't there at release is exactly the signal a stability-indicating method exists to catch. Two products here had that signal sitting unmonitored for months. Ask a blunt question of any stability data set: is it evaluating every peak generated, or just the ones the method was built to look for?
Third, "we'll test going forward" doesn't answer for product already shipped. That gap ran through all three citations: media fills after October 2026, peak monitoring going forward, reference-sample testing from now on. None of it addresses what's already in the U.S. market, and a response built only around future testing is a response built to fail FDA review.
FAQ
What products does the Sato Pharmaceutical warning letter cover?
OTC drug products manufactured at the firm's Hachioji, Tokyo facility, including sterile products made on its aseptic filling line. The letter does not name specific brands; all product identifiers are redacted.
Is Sato Pharmaceutical still making sterile drugs for the U.S. market?
No. The firm voluntarily halted sterile-drug production for the U.S. market. FDA wants a written commitment to keep that halt in place until corrective actions and a CAPA plan are finalized, or a written commitment to stop sterile manufacturing for the U.S. market permanently.
Did FDA accept Sato's response to the inspection findings?
No. FDA reviewed the firm's December 12, 2025 response and found it inadequate on all three citations, saying it addressed individual fixes rather than the systemic failures in aseptic design, stability testing, and microbiological controls.
Source: FDA Warning Letter 320-26-75, May 18, 2026. Byline: The Argus Regulatory Analysis Team. Published 2026-07-09.